Prodeon’s UrocrossTM Expander System and PURETM Procedure

An Investigational, Patient-Oriented BPH Treatment Using Flexible Cystoscopy

About Prodeon Medical, Inc.

The Prodeon Medical, Inc. initiative was started in 2016 with the mission of transforming the approach to treating lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). The company has designed a promising new minimally-invasive and more patient-friendly approach to treating LUTS from BPH: the Prostatic Urethral REshaping procedure (PURE) using the investigational Urocross™ Expander System and Retrieval Sheath. The PURE procedure is conducted by way of standard flexible cystoscopic techniques, where the implant is removed leaving no permanent foreign body behind**.

* Urocross™ was formerly branded as XFLO and Mercury
**The Urocross Expander is intended to be removed after a period of six months


Prodeon Medical Inc. is committed to delivering novel urological treatment options to patients, increasing clinicians’ treatment options and maximizing shareholder value.

Management Team

Paul Edwards
President and Chief Executive Officer

Nicole Haratani, RN, BSN
Executive Vice President, Clinical and Regulatory

Al Burdulis
Vice President, Research & Development and Operations

Kimberly Marquez
Senior Director, Quality Assurance

Board of Directors

Yue-Teh Jang, Ph.D.

Paul Edwards
President and Chief Executive Officer

Yi-Ju Chen, D.Phil.